Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 18/20 | 1.00 |
| ▸ | APAF1 | O14727 | 2/20 | 0.69 |
| ▸ | TDO2 | P48775 | 6/20 | 0.55 |
| ▸ | IDO2 | Q6ZQW0 | 6/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9885127 | 0.90 | IDO1 (0.81) | IDO1APAF1TDO2IDO2NPC1 | |
| SCHEMBL19456420 | 0.88 | IDO1 (0.78) | IDO1APAF1TDO2IDO2 | |
| SCHEMBL14442332 | 0.86 | IDO1 (1.00) | IDO1APAF1TDO2IDO2NPC1 | |
| SCHEMBL4586115 | 0.85 | IDO1 (0.75) | IDO1APAF1TDO2IDO2NPC1 | |
| SCHEMBL4587505 | 0.85 | IDO1 (1.00) | IDO1APAF1TDO2IDO2NPC1 | |
| SCHEMBL4593735 | 0.85 | IDO1 (0.75) | IDO1APAF1TDO2IDO2NPC1 | |
| SCHEMBL19456419 | 0.84 | IDO1 (0.73) | IDO1APAF1 | |
| SCHEMBL20597470 | 0.84 | IDO1 (0.73) | IDO1APAF1 | |
| SCHEMBL19456418 | 0.84 | IDO1 (0.73) | IDO1APAF1 | |
| SCHEMBL11983614 | 0.84 | IDO1 (0.72) | IDO1APAF1TDO2IDO2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190112308-A1 | Use of Aza-Tryptanthrin Derivatives as Inhibitors of IDO1 and/or TDO | PEKING UNIVERSITY (CN) | 2019-04-18 | — | — | US | claimed |
| EP-3421472-A1 | NITROGEN HETEROCYCLIC TRYPTAMINE KETONE DERIVATIVE AND APPLICATION AS IDO1 AND/OR TDO INHIBITOR | Peking University (CN) | 2019-01-02 | — | — | EP | claimed |
| US-20120244182-A1 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-09-27 | — | — | US | claimed |
| EP-1594524-B1 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2012-08-15 | — | — | EP | claimed |
| EP-1594524-A4 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-09-03 | — | — | EP | claimed |
| EP-1594524-A2 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | CHIRON CORPORATION (US) | 2005-11-16 | — | — | EP | claimed |
| US-20040241192-A1 | Use of tryptanthrin compounds for immune potentiation | CHIRON CORPORATION (US) | 2004-12-02 | — | — | US | claimed |
| WO-2004064759-A2 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | CHIRON CORPORATION (US) | 2004-08-05 | — | — | WO | claimed |
| EP-3421472-B1 | AZA-TRYPTANTHRIN DERIVATIVES AS IDO1 AND/OR TDO INHIBITORS | UNIV BEIJING (CN) | 2022-12-07 | — | — | EP | disclosed |
| EP-3421472-B1 | AZA-TRYPTANTHRIN DERIVATIVES AS IDO1 AND/OR TDO INHIBITORS | UNIV BEIJING (CN) | 2022-12-07 | — | — | EP | disclosed |
| US-10669273-B2 | Use of aza-tryptanthrin derivatives as inhibitors of IDO1 and/or TDO | PEKING UNIVERSITY (CN) | 2020-06-02 | — | — | US | disclosed |
| US-10669273-B2 | Use of aza-tryptanthrin derivatives as inhibitors of IDO1 and/or TDO | PEKING UNIVERSITY (CN) | 2020-06-02 | — | — | US | disclosed |
| US-20190112308-A1 | Use of Aza-Tryptanthrin Derivatives as Inhibitors of IDO1 and/or TDO | PEKING UNIVERSITY (CN) | 2019-04-18 | — | — | US | disclosed |
| US-20190112308-A1 | Use of Aza-Tryptanthrin Derivatives as Inhibitors of IDO1 and/or TDO | PEKING UNIVERSITY (CN) | 2019-04-18 | — | — | US | disclosed |
| US-8012987-B2 | Indolo[2,1-b] quinazole-6,12-dione antimalarial compounds and methods of treating malaria therewith | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012987-B2 | Indolo[2,1-b] quinazole-6,12-dione antimalarial compounds and methods of treating malaria therewith | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2011-09-06 | — | — | US | disclosed |
| US-7259167-B2 | Antimalarial and antiproliferative pharmacophore models, novel tryptanthrin compounds having increased solubility, and methods of making and using thereof | UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2007-08-21 | — | — | US | disclosed |
| US-7259167-B2 | Antimalarial and antiproliferative pharmacophore models, novel tryptanthrin compounds having increased solubility, and methods of making and using thereof | UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2007-08-21 | — | — | US | disclosed |
| EP-1032574-B1 | INDOLO 2,1-b|QUINAZOLE-6,12-DIONE ANTIMALARIAL COMPOUNDS AND METHODS OF TREATING MALARIA THEREWITH | US ARMY (US) | 2007-06-13 | — | — | EP | disclosed |
| US-20040241192-A1 | Use of tryptanthrin compounds for immune potentiation | CHIRON CORPORATION (US) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669273-B2 | Use of aza-tryptanthrin derivatives as inhibitors of IDO1 and/or TDO | IDO1, TDO2, IDO2 | IDO1 1/4885APAF1 1887/4885TDO2 2/4885 |
| US-20120244182-A1 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | TPSG1, TPSB2, TPSAB1 | IDO1 20/4885APAF1 928/4885TDO2 66/4885 |
| US-20040241192-A1 | Use of tryptanthrin compounds for immune potentiation | TPSG1, TPSB2, TPSAB1 | IDO1 20/4885APAF1 928/4885TDO2 66/4885 |
| US-20190112308-A1 | Use of Aza-Tryptanthrin Derivatives as Inhibitors of IDO1 and/or TDO | IDO1, TDO2, IDO2 | IDO1 1/4885APAF1 1887/4885TDO2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.